These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33277348)

  • 1. Increased Levels of Renal Lysophosphatidic Acid in Rodent Models with Renal Disease.
    Hirata T; Smith SV; Takahashi T; Miyata N; Roman RJ
    J Pharmacol Exp Ther; 2021 Feb; 376(2):240-249. PubMed ID: 33277348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.
    Li HY; Oh YS; Choi JW; Jung JY; Jun HS
    Kidney Int; 2017 Jun; 91(6):1362-1373. PubMed ID: 28111010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LPA1 receptor activation promotes renal interstitial fibrosis.
    Pradère JP; Klein J; Grès S; Guigné C; Neau E; Valet P; Calise D; Chun J; Bascands JL; Saulnier-Blache JS; Schanstra JP
    J Am Soc Nephrol; 2007 Dec; 18(12):3110-8. PubMed ID: 18003779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a lysophosphatidic acid receptor 1 antagonist on hypertensive renal injury in Dahl-Iwai salt-sensitive rats.
    Naruse T; Otake H; Takahashi T
    J Pharmacol Sci; 2022 Aug; 149(4):179-188. PubMed ID: 35717071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase.
    Lee JH; Sarker MK; Choi H; Shin D; Kim D; Jun HS
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1332-1340. PubMed ID: 30763641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.
    Williams JM; Zhang J; North P; Lacy S; Yakes M; Dahly-Vernon A; Roman RJ
    Am J Physiol Renal Physiol; 2011 Apr; 300(4):F983-98. PubMed ID: 21228113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of bioactive lysophosphatidic acid in renal effluent of rats with unilateral ureteral obstruction.
    Tsutsumi T; Adachi M; Nikawadori M; Morishige J; Tokumura A
    Life Sci; 2011 Aug; 89(5-6):195-203. PubMed ID: 21693124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the development of renal injury in Type-1 diabetic Dahl salt-sensitive rats.
    Slaughter TN; Paige A; Spires D; Kojima N; Kyle PB; Garrett MR; Roman RJ; Williams JM
    Am J Physiol Regul Integr Comp Physiol; 2013 Oct; 305(7):R727-34. PubMed ID: 23926133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ChREBP ubiquitination via the ROS/Akt-dependent downregulation of Smurf2 contributes to lysophosphatidic acid-induced fibrosis in renal mesangial cells.
    Kim D; Nam GY; Seo E; Jun HS
    J Biomed Sci; 2022 May; 29(1):31. PubMed ID: 35538534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effects of empagliflozin in type 1 and type 2 models of diabetic nephropathy superimposed with hypertension.
    Williams JM; Murphy SR; Wu W; Border JJ; Fan F; Roman RJ
    Geroscience; 2022 Dec; 44(6):2845-2861. PubMed ID: 35767209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic Acid Signaling in Diabetic Nephropathy.
    Lee JH; Kim D; Oh YS; Jun HS
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Cellular Repressor of E1A-Stimulated Genes Protects against Renal Fibrosis in Dahl Salt-Sensitive Rats.
    Liu ML; Song HX; Tian XX; Liu YX; Liu D; Hou ZW; Li JY; Yan CH; Han YL
    Am J Nephrol; 2020; 51(5):401-410. PubMed ID: 32320986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
    Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
    Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased urinary lysophosphatidic acid in mouse with subtotal nephrectomy: potential involvement in chronic kidney disease.
    Mirzoyan K; Baïotto A; Dupuy A; Marsal D; Denis C; Vinel C; Sicard P; Bertrand-Michel J; Bascands JL; Schanstra JP; Klein J; Saulnier-Blache JS
    J Physiol Biochem; 2016 Dec; 72(4):803-812. PubMed ID: 27637780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of the progression of renal injury in diabetic rodent models with preexisting renal disease with chronic endothelin A receptor blockade.
    Spires D; Poudel B; Shields CA; Pennington A; Fizer B; Taylor L; McPherson KC; Cornelius DC; Williams JM
    Am J Physiol Renal Physiol; 2018 Oct; 315(4):F977-F985. PubMed ID: 29846112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice.
    Rancoule C; Attané C; Grès S; Fournel A; Dusaulcy R; Bertrand C; Vinel C; Tréguer K; Prentki M; Valet P; Saulnier-Blache JS
    Diabetologia; 2013 Jun; 56(6):1394-402. PubMed ID: 23508306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QiShenYiQi ameliorates salt-induced hypertensive nephropathy by balancing ADRA1D and SIK1 expression in Dahl salt-sensitive rats.
    Du H; Xiao G; Xue Z; Li Z; He S; Du X; Zhou Z; Cao L; Wang Y; Yang J; Wang X; Zhu Y
    Biomed Pharmacother; 2021 Sep; 141():111941. PubMed ID: 34328102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced kidney levels of lysophosphatidic acids in rats after chronic administration of aristolochic acid: Its possible protective role in renal fibrosis.
    Tsutsumi T; Yamakawa S; Ishihara A; Yamamoto A; Tanaka T; Tokumura A
    Toxicol Rep; 2015; 2():121-129. PubMed ID: 28962344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pro-fibrotic activity of lysophosphatidic acid in adipose tissue: in vivo and in vitro evidence.
    Rancoule C; Viaud M; Gres S; Viguerie N; Decaunes P; Bouloumié A; Langin D; Bascands JL; Valet P; Saulnier-Blache JS
    Biochim Biophys Acta; 2014 Jan; 1841(1):88-96. PubMed ID: 24120919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
    Uchii M; Kimoto N; Sakai M; Kitayama T; Kunori S
    Eur J Pharmacol; 2016 Jul; 783():56-63. PubMed ID: 27063445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.